In the fourth decade of p53 investigation the research community hopes to be able to get new drugs to affect p53 function to treat not only cancer but also important neurological conditions, such as AD.The recognition of HIPK2 as new target of the effect of Aβ could suggest a new putative functional biomarker useful in addressing new therapeutic strategies [90]. The gene discussed is TP53; the disease is Alzheimer disease.